94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
REVIEW article
Front. Endocrinol.
Sec. Reproduction
Volume 16 - 2025 | doi: 10.3389/fendo.2025.1576333
This article is part of the Research Topic Ovarian Aging: Pathophysiology and Recent Development of Maintaining Ovarian Reserve, Volume IV View all 3 articles
Novel Perspectives on Growth Hormone Regulation of Ovarian Function: Mechanisms, Formulations, and Therapeutic Applications
Provisionally accepted- 1 Shandong First Medical University, Tai'an, Shandong, China
- 2 Department of Reproductive Medicine, Shandong Provincial Hospital, Jinan, China
- 3 Shandong Key Laboratory of Reproductive Research and Birth Defect Prevention and Jinan Engineering Laboratory of Reproductive Diagnosis and Treatment Technology, Shandong First Medical University, Tai'an, Shandong, China
- 4 Shandong Second Medical University, Weifang, Shandong Province, China
Delayed childbearing has led to a continuous rise in the incidence of infertility because of social development and the evolving roles of women. Assisted reproductive technology (ART) has provided new opportunities for infertility treatment, such as the application of growth hormone (GH). GH regulates ovarian function through multiple pathways, improving follicular development and hormone secretion. However, traditional GH therapy is limited by issues such as low bioavailability and insufficient delivery efficiency. In recent years, drug delivery systems based on novel biomaterials have provided breakthrough solutions for the innovative application of GH in ART. This review summarizes the mechanisms by which GH affects ovarian endocrine function and focuses on the cutting-edge advancements in GH delivery systems with examination of the innovative applications of composite biomaterials in enhancing the therapeutic efficacy of GH. By analyzing the pharmacokinetic properties of novel formulations, the safety and long-term efficacy of their clinical applications can be evaluated. GH delivery systems based on novel biomaterials considerably improve the bioavailability and targeting of GH, and could lead to innovative therapeutic strategies for preventing and treating ovarian dysfunction and related diseases. By integrating multidisciplinary research findings, we provide new insights into the field of reproductive medicine that could lead to theoretical and practical importance for promoting the innovative development of ART.
Keywords: Assisted Reproductive Technology, Growth Hormone, PREMATURE OVARIAN INSUFFICIENCY, Follicular development, Infertility
Received: 13 Feb 2025; Accepted: 24 Mar 2025.
Copyright: © 2025 Yang, Luo, Sun and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Shan Wang, Department of Reproductive Medicine, Shandong Provincial Hospital, Jinan, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.